Andreas Neubauer
YOU?
Author Swipe
View article: Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients Open
In the European LeukemiaNet (ELN) 2022 recommendations, myelodysplasia-related (MR) gene mutations were classified as a novel adverse prognostic category for intensively treated acute myeloid leukemia (AML). To assess the prognostic impact…
View article: Detection of minimal residual disease in circulating cell-free DNA in acute myeloid leukemia
Detection of minimal residual disease in circulating cell-free DNA in acute myeloid leukemia Open
Minimal/measurable residual disease (MRD) in Acute Myeloid Leukemia (AML) is defined as persistent leukemic cells below cytomorphological detection threshold. Next generation sequencing (NGS) of circulating cell-free DNA (cfDNA) to profile…
View article: Mutation-based, neoadjuvant treatment for advanced anaplastic thyroid carcinoma
Mutation-based, neoadjuvant treatment for advanced anaplastic thyroid carcinoma Open
Introduction The prognosis of anaplastic thyroid carcinoma (ATC) remains poor. Mutation-based targeted therapies and immune checkpoint inhibitors (ICI) have gained increasing importance in the treatment of advanced tumor stages. This study…
View article: Self-explaining Artificial Intelligence for the Classification of B cell Non-Hodgkin Lymphoma
Self-explaining Artificial Intelligence for the Classification of B cell Non-Hodgkin Lymphoma Open
Artificial intelligence (AI) systems have been proposed for multiparameter flow cytometry (MFC) based immunophenotyping of leukemic Non-Hodgkin-Lymphoma (NHL). Lymphoma classification has progressively been revised due to the increasing mo…
View article: Genetic engineering of primary human mesenchymal stromal cells using the CRISPR/Cas9 synergistic activation mediator
Genetic engineering of primary human mesenchymal stromal cells using the CRISPR/Cas9 synergistic activation mediator Open
Background: Genomic editing technologies provide rich opportunities to approach inherited human diseases, but gene delivery strategies are still challenging. While engineered induced pluripotent stem cells or adeno-associated viral vectors…
View article: The Positive Effect of pro‐Environmental Behavior on Eudaimonic Well‐Being in Young Adults: A Daily Diary Study Using the Within‐Person Encouragement Design
The Positive Effect of pro‐Environmental Behavior on Eudaimonic Well‐Being in Young Adults: A Daily Diary Study Using the Within‐Person Encouragement Design Open
Introduction Existing literature has highlighted the relevance of Pro‐environmental behaviors (PEBs)—actions intended to benefit the environment—to Eudaimonic well‐being (EWB, i.e., meaning in life and connectedness to others). However, mo…
View article: Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia‐Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the <scp>EBMT</scp>
Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia‐Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the <span>EBMT</span> Open
Patients (pts) with myelodysplasia‐related AML (MR‐AML) are now genetically recategorized, with three different groups in the International Consensus Classification: AML with mutated TP53 (TP53‐AML), with myelodysplasia‐related gene mutati…
View article: The <scp> <i>IKZF1</i> N159S </scp> mutation is associated with poor outcome and a distinct molecular profile in adult patients with <scp>AML</scp>
The <span> <i>IKZF1</i> N159S </span> mutation is associated with poor outcome and a distinct molecular profile in adult patients with <span>AML</span> Open
Summary IKZF1 mutations are recurrent alterations in acute myeloid leukaemia (AML), and hotspot point mutation, N159S, has recently been associated with unique gene expression and adverse risk. To better understand the molecular and clinic…
View article: Real-time mechanism-based interventions for daily alcohol challenges: Protocol for ecological momentary assessment and intervention
Real-time mechanism-based interventions for daily alcohol challenges: Protocol for ecological momentary assessment and intervention Open
Background Advancing evidence-based, tailored interventions for substance use disorders (SUDs) requires understanding temporal directionality while upholding ecological validity. Previous studies identified loneliness and craving as pivota…
View article: Causal effects of sedentary breaks on affective and cognitive parameters in daily life: a within-person encouragement design
Causal effects of sedentary breaks on affective and cognitive parameters in daily life: a within-person encouragement design Open
Understanding the complex relationship between sedentary breaks, affective well-being and cognition in daily life is critical as modern lifestyles are increasingly characterized by sedentary behavior. Consequently, the World Health Organiz…
View article: The role of allogeneic stem cell transplantation in acute myeloid leukemia with translocation t(8;16)(p11;p13)
The role of allogeneic stem cell transplantation in acute myeloid leukemia with translocation t(8;16)(p11;p13) Open
Acute myeloid leukemia (AML) with translocation t(8;16)(p11;p13) represents a rare entity that has been categorized as a disease‐defining recurring cytogenetic abnormality with adverse risk in the 2022 European LeukemiaNet classification. …
View article: Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia
Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia Open
In 2022, the European LeukemiaNet (ELN) risk stratification for patients with acute myeloid leukemia (AML) has been updated. We aimed to validate the prognostic value of the 2022 ELN classification (ELN22) by evaluating 1570 patients with …
View article: The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients Open
Secondary-type mutations (STM) are defined as alterations in ASXL1, BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2 in the recent update of the WHO classification on myeloid neoplasms. The International Consensus Classification (ICC) ext…
View article: Impact of <i>TP53</i> Mutation Status in Elderly <scp>AML</scp> Patients When Adding All‐<i>Trans</i> Retinoic Acid or Valproic Acid to Decitabine
Impact of <i>TP53</i> Mutation Status in Elderly <span>AML</span> Patients When Adding All‐<i>Trans</i> Retinoic Acid or Valproic Acid to Decitabine Open
In a randomized phase II trial (AMLSG 14‐09, NCT00867672) of elderly, newly diagnosed AML patients, ATRA combined with decitabine (DEC) significantly improved the overall response rate (ORR) and survival also in patients with adverse‐risk …
View article: Real‐world effectiveness of first‐line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy
Real‐world effectiveness of first‐line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy Open
Background First‐line treatment in patients with acute myeloid leukemia (AML) unfit for intensive therapy is the combination of a hypomethylating agent (HMA) with venetoclax (VEN). However, retrospective data confirming the benefits of thi…
View article: Peripheral blood stem cell versus bone marrow graft for patients ≥60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Peripheral blood stem cell versus bone marrow graft for patients ≥60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Open
In the context of T‐cell replete haploidentical stem cell transplantation (Haplo‐SCT) using post‐transplantation cyclophosphamide (PT‐Cy), it is still unknown whether peripheral blood (PB) or bone marrow (BM) is the best graft source. Whil…
View article: IRF2BP2 counteracts the ATF7/JDP2 AP-1 heterodimer to prevent inflammatory overactivation in acute myeloid leukemia (AML) cells
IRF2BP2 counteracts the ATF7/JDP2 AP-1 heterodimer to prevent inflammatory overactivation in acute myeloid leukemia (AML) cells Open
Acute myeloid leukemia (AML) is a hematological malignancy characterized by abnormal proliferation and accumulation of immature myeloid cells in the bone marrow. Inflammation plays a crucial role in AML progression, but excessive activatio…
View article: Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial
Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial Open
We hypothesized that fit older patients with acute myeloid leukemia (AML) treated with decitabine (DEC) would report better health-related quality of life (HRQoL) outcomes than those receiving intensive chemotherapy (IC). We conducted a ph…
View article: Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens Open
In newly diagnosed acute myeloid leukemia, immediate initiation of treatment is standard of care. However, deferral of antileukemic therapy may be indicated to assess comorbidities or pre-therapeutic risk factors. We explored the impact of…
View article: Trustworthy and Self-explanatory Artificial Intelligence for the Classification of Non-Hodgkin Lymphoma by Immunophenotype
Trustworthy and Self-explanatory Artificial Intelligence for the Classification of Non-Hodgkin Lymphoma by Immunophenotype Open
Diagnostic immunophenotyping of malignant non-Hodgkin-lymphoma (NHL) by multiparameter flow cytometry (MFC) relies on highly trained physicians. Artificial intelligence (AI) systems have been proposed for this diagnostic task, often requir…
View article: NGS-Guided Precision Oncology in Breast Cancer and Gynecological Tumors—A Retrospective Molecular Tumor Board Analysis
NGS-Guided Precision Oncology in Breast Cancer and Gynecological Tumors—A Retrospective Molecular Tumor Board Analysis Open
Background: Precision oncology treatments are being applied more commonly in breast and gynecological oncology through the implementation of Molecular Tumor Boards (MTBs), but real-world clinical outcome data remain limited. Methods: A ret…
View article: A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1
A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1 Open
Adjuvant treatment for Glioblastoma Grade 4 with Temozolomide (TMZ) inevitably fails due to therapeutic resistance, necessitating new approaches. Apoptosis induction in GB cells is inefficient, due to an excess of anti-apoptotic XPO1/Bcl-2…